A method for screening and validation of resistant mutations against kinase inhibitors
Related Experiment Video
Updated: Apr 19, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Meenu Kesarwani1, Erika Huber1, Zachary Kincaid1
1Divisions of Experimental Hematology and Cancer Pathology, Cancer Blood Disease Institute, Cincinnati Children's Hospital Medical Center.
Abstract:
The discovery of BCR/ABL as a driver oncogene in chronic myeloid leukemia (CML) resulted in the development of Imatinib, which, in fact, demonstrated the potential of targeting the kinase in cancers by effectively treating the CML patients. This observation revolutionized drug development to target the oncogenic kinases implicated in various other malignancies, such as, EGFR, B-RAF, KIT and PDGFRs. However, one major drawback of anti-kinase therapies is the emergence of drug resistance mutations rendering the target to have reduced or lost affinity for the drug. Understanding the mechanisms employed by resistant variants not only helps in developing the next generation inhibitors but also gives impetus to clinical management using personalized medicine. We reported a retroviral vector based screening strategy to identify the spectrum of resistance conferring mutations in BCR/ABL, which has helped in developing the next generation BCR/ABL inhibitors. Using Ruxolitinib and JAK2 as a drug target pair, here we describe in vitro screening methods that utilizes the mouse BAF3 cells expressing the random mutation library of JAK2 kinase.
Insights
Researchers developed an in vitro screening method to identify drug resistance mutations in Janus kinase 2 (JAK2). This approach aids in understanding resistance mechanisms and developing next-generation kinase inhibitors for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Targeting oncogenic kinases like BCR/ABL with drugs such as Imatinib has revolutionized cancer treatment.
- Drug resistance mutations frequently emerge, reducing therapeutic efficacy and necessitating new treatment strategies.
- Understanding resistance mechanisms is crucial for developing next-generation inhibitors and personalized medicine.
Purpose of the Study:
- To describe in vitro screening methods for identifying drug resistance mutations in kinases.
- To utilize Ruxolitinib and Janus kinase 2 (JAK2) as a model system for this screening.
- To generate a random mutation library of JAK2 kinase for screening.
Main Methods:
- Development of a retroviral vector-based screening strategy.
- Creation of a random mutation library of JAK2 kinase.
- Utilizing mouse BAF3 cells expressing the JAK2 mutation library for in vitro screening.
Main Results:
- The study describes a novel in vitro screening method for kinase resistance mutations.
- The method employs a random mutation library of JAK2 expressed in mouse BAF3 cells.
- This approach facilitates the identification of mutations conferring resistance to kinase inhibitors like Ruxolitinib.
Conclusions:
- The described in vitro screening method is effective for identifying drug resistance mutations in kinases.
- This methodology aids in understanding resistance mechanisms and developing next-generation kinase inhibitors.
- The approach has implications for personalized medicine and improved cancer treatment strategies.
